Related Experiment Videos
Short-term sexual function after prostate brachytherapy
G S Merrick1, K Wallner, W M Butler
1Schiffler Cancer Center, Wheeling Hospital, 1 Medical Park, Wheeling, WV 26003-6300, USA. schifonc@wheelinghosp.com
International Journal of Cancer
|October 3, 2001
Summary
Prostate brachytherapy using iodine-125 or palladium-103 maintained sexual function in most patients. Sildenafil was effective for erectile dysfunction, with 76.5% achieving intercourse capability.
Area of Science:
- Urology
- Oncology
- Radiation Oncology
Background:
- Low-risk prostate cancer treatment often involves brachytherapy.
- Assessing sexual function post-treatment is crucial for quality of life.
Purpose of the Study:
- To evaluate sexual function in patients with low-risk prostate cancer treated with brachytherapy.
- To compare outcomes between iodine-125 and palladium-103 isotopes.
Main Methods:
- Phase III prospective randomized trial.
- 34 patients with low-risk prostate cancer (PSA ≤ 10, Gleason ≤ 6, Stage T1/T2).
- International Index of Erectile Function (IIEF) scores and side effect documentation.
Main Results:
- No significant difference in IIEF scores between iodine-125 and palladium-103.
- 35% experienced severe erectile dysfunction (IIEF < 6).
- 65% maintained sexual function without medication; 76.5% with sildenafil support.
Conclusions:
- Prostate brachytherapy is associated with significant rates of sexual dysfunction.
- Sildenafil is an effective treatment for post-brachytherapy erectile dysfunction.
- Most patients can achieve intercourse capability with or without pharmacologic support.